CN115003295B - 具有雌激素受体降解活性的新型色满衍生物及其用途 - Google Patents

具有雌激素受体降解活性的新型色满衍生物及其用途 Download PDF

Info

Publication number
CN115003295B
CN115003295B CN202080092528.XA CN202080092528A CN115003295B CN 115003295 B CN115003295 B CN 115003295B CN 202080092528 A CN202080092528 A CN 202080092528A CN 115003295 B CN115003295 B CN 115003295B
Authority
CN
China
Prior art keywords
cancer
compound
phenyl
piperidin
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080092528.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN115003295A (zh
Inventor
范捷
Y.钱
W.何
刘坷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accutar Biotechnology Inc
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Priority to CN202510495956.1A priority Critical patent/CN120665056A/zh
Publication of CN115003295A publication Critical patent/CN115003295A/zh
Application granted granted Critical
Publication of CN115003295B publication Critical patent/CN115003295B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080092528.XA 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途 Active CN115003295B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510495956.1A CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947213P 2019-12-12 2019-12-12
US62/947,213 2019-12-12
PCT/US2020/027895 WO2021118629A1 (en) 2019-12-12 2020-04-13 Novel chroman derivatives having estrogen receptor degradation activity and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510495956.1A Division CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Publications (2)

Publication Number Publication Date
CN115003295A CN115003295A (zh) 2022-09-02
CN115003295B true CN115003295B (zh) 2025-05-06

Family

ID=70289288

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080092528.XA Active CN115003295B (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途
CN202510495956.1A Pending CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510495956.1A Pending CN120665056A (zh) 2019-12-12 2020-04-13 具有雌激素受体降解活性的新型色满衍生物及其用途

Country Status (11)

Country Link
US (2) US10800770B1 (https=)
EP (2) EP3835298B1 (https=)
JP (2) JP7662639B2 (https=)
KR (1) KR102942706B1 (https=)
CN (2) CN115003295B (https=)
CA (1) CA3164202A1 (https=)
DK (1) DK3835298T3 (https=)
ES (1) ES2986594T3 (https=)
FI (1) FI3835298T3 (https=)
MX (1) MX2022007155A (https=)
WO (1) WO2021118629A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
EP3932922A4 (en) 2019-02-25 2022-05-11 ShanghaiTech University SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
WO2021023233A1 (zh) 2019-08-05 2021-02-11 上海科技大学 Egfr蛋白降解剂及其抗肿瘤应用
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
FI3835298T3 (fi) * 2019-12-12 2024-07-29 Accutar Biotechnology Inc Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja
WO2021133886A1 (en) * 2019-12-23 2021-07-01 Accutar Biotechnology Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
CA3169011A1 (en) * 2020-02-25 2021-09-02 Xiaobao Yang Glutarimide skeleton-based compounds and uses thereof
AR123492A1 (es) 2020-09-14 2022-12-07 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
EP4289841A4 (en) * 2021-02-04 2025-02-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
WO2022187588A1 (en) * 2021-03-04 2022-09-09 The Regents Of The University Of Michigan Small molecule degraders of estrogen receptor with cereblon ligands
MX2023011166A (es) * 2021-03-29 2023-09-29 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
EP4377296A1 (en) 2021-07-26 2024-06-05 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound
AU2022370021B2 (en) * 2021-10-22 2026-04-16 Gluetacs Therapeutics (Shanghai) Co., Ltd. Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
CN113816927B (zh) * 2021-11-23 2022-02-25 苏州国匡医药科技有限公司 一种arv-471中间体的制备方法
CN117229286A (zh) 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2024015409A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Chroman derivatives as estrogen receptor degraders
CN116751186B (zh) * 2022-12-23 2024-10-18 南京知和医药科技有限公司 一种雌激素受体调节剂的制备及其用途
WO2024153025A1 (zh) * 2023-01-16 2024-07-25 南京明德新药研发有限公司 取代的苯并七元环化合物及其应用
CN119258223A (zh) * 2023-07-06 2025-01-07 海创药业股份有限公司 一种降解雌激素受体的联合用药物及其用途
WO2025245408A1 (en) 2024-05-22 2025-11-27 Accutar Biotechnology Inc. Chroman-based compounds for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495618A (zh) * 2016-07-12 2018-09-04 冰洲石生物科技公司 新的化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021710A1 (en) * 1996-10-28 2001-09-13 Poul Jacobsen Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129627A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129618A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
WO2003063659A1 (de) 2002-02-01 2003-08-07 Danny Bellens Ablageständer
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP3303326B1 (en) * 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
KR102674902B1 (ko) * 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
FI3835298T3 (fi) * 2019-12-12 2024-07-29 Accutar Biotechnology Inc Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495618A (zh) * 2016-07-12 2018-09-04 冰洲石生物科技公司 新的化合物及其用途

Also Published As

Publication number Publication date
US20210221802A1 (en) 2021-07-22
FI3835298T3 (fi) 2024-07-29
JP2023506155A (ja) 2023-02-15
MX2022007155A (es) 2022-10-07
CA3164202A1 (en) 2021-06-17
US11261178B2 (en) 2022-03-01
WO2021118629A1 (en) 2021-06-17
DK3835298T3 (da) 2024-07-29
EP4420728A2 (en) 2024-08-28
EP3835298A1 (en) 2021-06-16
KR20220118460A (ko) 2022-08-25
ES2986594T3 (es) 2024-11-12
KR102942706B1 (ko) 2026-03-20
EP4420728A3 (en) 2024-10-30
CN120665056A (zh) 2025-09-19
US10800770B1 (en) 2020-10-13
JP2025081364A (ja) 2025-05-27
JP7662639B2 (ja) 2025-04-15
EP3835298B1 (en) 2024-06-26
CN115003295A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
CN115003295B (zh) 具有雌激素受体降解活性的新型色满衍生物及其用途
CN113164409B (zh) 具有雌激素受体α降解活性的化合物及其用途
CN111225896B (zh) 免疫调节剂化合物
CN113329999B (zh) 具有雄激素受体降解活性的新型取代的喹啉-8-甲腈衍生物及其用途
WO2020114482A1 (zh) 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
WO2021061644A1 (en) Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
RU2727705C1 (ru) Производное бензопиперидина, способ его получения и его медицинское применение
WO2019085933A1 (zh) 作为Wee1抑制剂的大环类化合物及其应用
EP3312184A1 (en) Piperidine derivative and preparation method and pharmaceutical use thereof
JP2022549222A (ja) アンドロゲン受容体分解活性を有する新規尿素およびその使用
RU2722441C2 (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
US20220064176A1 (en) Isocarbostyril alkaloids and functionalization thereof
CN116438177B (zh) 靶向嵌合化合物、含其的药物组合物及其制备方法和用途
HK40080061A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
CA2985021A1 (en) Selective modulators of the activity of the gpr55 receptor: chromenopyrazole derivatives
HK40080061B (zh) 具有雌激素受体降解活性的新型色满衍生物及其用途
HK40115205A (en) Novel chroman derivatives having estrogen receptor degradation activity and uses thereof
JP2009517357A (ja) イソキノリンおよびベンゾ［ｈ］イソキノリン誘導体、調製およびヒスタミンｈ３受容体のアンタゴニストとしてのこの治療上の使用
HK40058838A (en) Novel compounds having estrogen receptor alpha degradation activity and uses thereof
KR20260040160A (ko) Cyp11a1 억제제로서의 신규 화합물 및 그 용도
KR20090034787A (ko) 모르피난 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080061

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant